欢迎来到天天文库
浏览记录
ID:5342420
大小:995.24 KB
页数:3页
时间:2017-12-08
《循环应用cag,ia方案治疗高危骨髓增生异常综合征临床疗效观察》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、..潍坊医学院学报2010年第32卷第3期173doi:10.3969/j.issn.1004-3101.2010.03.004循环应用CAG,IA方案治疗高危骨髓增生异常综合征临床疗效观察徐文君,任翠爱,崔景英,王宝宏,冉学红(潍坊医学院附属潍坊市人民医院血液科,山东潍坊261041)CyclicApplicationofCAGandIARegimensintheTreatmentofAdvancedMyelodysplasticSyndromeXUWen-jun,RENCui·ai,CUIJing-ying,WANGBao—hong,RANXue
2、—hong(HematologyDepartmentofWeifangPeople"sHospitalAfiliatedtoWe扣ngMedicalCollege,Weifang261041,China)[ABSTRACT]ObjectiveToobservetheclinicaleficacyofcyclicapplicationofCAGandIAregimensinthetreatmentofhigh—riskmyelodysplasticsyndrome(MDS).MethodsTwelvepatientswithhigh—riskMDSwe
3、reenrolledinthistrialtoaccepttheinductionremissiontherapyofCAGregimenwhichincludesaclarubicin,arabinosykytosineandgranulocytecolony—stimulatingfactoratfirst.IfCRorPRreachedthenAra—Cregimenwasapplied,otherwise,IAregimenwasappliedafterthesameCAGregimenagain(invalidoneswereoutofth
4、etria1).Thenafter3~4weeks,CAGandIAregimenswereappliedincircles(3~5circlesoneyear),thespecificdoseandcycleofwhichwasdependingonindivid。ua1.ResultsTwopatientsachievedCR(16.7%)and7patientsachievedPR,other3hadnoresponse。thetotaleffec.tiveratereachedto75%.Themediansurvivaltimewas18m
5、onths(6~40months),1.yearoverallsurvivalratewas83.3%,2-yearoverallsurvivalratewas58.3%and3yearoveral1survivalratewas16.7%.ToxicsideefiectWaslessseri—OUS,thedeathrateofchemotherapywas9.3%.ConclusionTheclinicaleficacyofcyclicapplicationofCAGandIAregimensinthetreatmentofhigh—riskMD
6、Sissafeandeffective.CHGregimenhashighresponserateandmildtoxicsideect.[KEYwombs]Myelodysplasticsyndrome;Granulocytecolony.stimulatingfactor;Arabinosylcytosine;Aclarubi—cin;Darubicin[作者简介]徐文君(1985年~),女(汉族),山东省潍坊市人,在读硕士研究生。主要研究方向:血液病。l74ActaAcadMedWeifangVoZ.32.32010骨髓增生异常综合征(MDS)
7、是一组累及一系或应用4~6次,视患者个体情况调整化疗药物用药剂量多系血细胞的异质恶性克隆性疾病,今年来发病率逐及周期。渐增高,其临床特点主要是骨髓衰竭和向急性白血病患者在治疗过程中定期接受血常规、肝肾功能以发展。MDS不同亚型之间的发病机制差异很大,决及凝血功能检测,心电图和胸部x线片检查,关注并定了其临床转归的不同,低危MDS生存期可达数年,记录患者临床表现,如胃肠道反应、体温、黏膜炎、脱发高危患者仅能存活半年~1年,大多数转化为急性白和感染情况等。当外周血血红蛋白<60g/L或血小板血病。针对高危MDS,本研究应用阿克拉霉素(aclaru.(BP
8、C)计数<20×10/L,予以成分输血;粒细胞缺乏bicin,Acla)和阿糖胞苷(arabinosylcy
此文档下载收益归作者所有